Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States.
Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School and Harvard Medical School, Boston, MA, United States; School of Medicine, University of California, San Diego, La Jolla, CA, United States.
Methods. 2020 May 1;177:58-66. doi: 10.1016/j.ymeth.2020.02.003. Epub 2020 Feb 12.
The past decade has witnessed a rapid growth in the field of extracellular vesicle (EV) based biomarkers for the diagnosis and monitoring of cancer. Several studies have reported novel EV based biomarkers, but the technical and clinical validation phase has been hampered by general challenges common to biomedical research field as well as specific challenges inherent to the nanoparticle field. This has led to more common failures than success stories in the biomarker discovery pipeline. As a result, more attention must be focused on the process of biomarker discovery, verification, and validation to allow for translation and application of novel EV based research to patient care. Herein, we briefly discuss the hurdles and potential solutions in EV biomarker discovery and verification and validation, and clinical translation.
过去十年见证了基于细胞外囊泡（EV）的生物标志物在癌症诊断和监测方面的快速发展。多项研究报道了新的基于 EV 的生物标志物，但技术和临床验证阶段受到了生物医学研究领域常见挑战以及纳米颗粒领域固有挑战的阻碍。这导致生物标志物发现管道中的失败案例多于成功案例。因此，必须更加关注生物标志物发现、验证和验证的过程，以将新的基于 EV 的研究转化并应用于患者护理。在此，我们简要讨论 EV 生物标志物发现、验证和验证以及临床转化中的障碍和潜在解决方案。
